Skip Navigation Links
 تاریخ های مهم 
 Pre Registered 
 برنامه همایش 
 Personal page 
                             دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد        شب بهاری چشم پزشکی با رحیم شهریاری       دومین همایش بهاره چشم پزشکی
Skip Navigation Links
        مکان برگزاری
        تاریخ های مهم
        ثبت نام
        ثبت نام شدگان
        برنامه همایش
        صفحه شخصی
        جستجوی سخنران
مقاله Abstract

Title: Brachytherapy in patients with recurrent ocular surface squamous neoplasia: a case series study
Author(s): Saeid Karimi, Azin Ashnagar, Pouyan Pahlevani
Presentation Type: Poster
Subject: Lens and Cataract
Presenting Author:
Name: Pouyan Pahlevani
Affiliation :(optional) Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Torfeh Eye Hospital, Tehran, Iran
E mail:
Mobile: 09183511175

To report outcomes of plaque brachytherapy in treating patients with recurrent ocular surface squamous neoplasia (OSSN).


We identified 3 patients with recurrent OSSN at department of ophthalmology in Torfeh hospital. All of them have been underwent excisional biopsy and after recurrence they didn't respond to local chemotherapy with interferon α2b. None of them had clinical or paraclinical evidence of intraocular invasion or metastasis. In all cases CIA Ru-106 plaque was placed on a meridian with maximal recurrence. The plaque was removed after reach mean target dose of 100 Gy. The whole procedures were performed by the same surgeon. Patients were followed up in mean period of 14 months.


Four eyes of 3 patients (2male, 1female) with recurrent of conjunctival SCC were reviewed. Mean age of patients was 66year. The maximal tumor diameter was 11 mm. After brachytherapy patients declare improvement in their symptoms. Decrease of inflammation and vascularity pattern were observed. No intraocular complication was reported


This case series demonstrate the role of plaque brachytherapy in treatment of recurrent and resistant conjunctival OSSN, which has more efficacy and lesser complication in compare with conventional standard treatment (Excision and MMC and INFα2b). So, it could be considered as a primary treatment for this disease

Attachment: 71poster 2.pptx

Last News

  - دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد
  -  شب بهاری چشم پزشکی با رحیم شهریاری
  - دومین همایش بهاره چشم پزشکی